Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Structural drivers of drug shortages and market withdrawal: a longitudinal analysis of the Romanian pharmaceutical market.
Structural Patterns of Antibiotic Shortages: A Cross-National Analysis of Systemic Antibacterials.
Melissopalynological and Physicochemical Analysis of Selected Honey Samples from Romania, Spain, Malaysia, and New Zealand.
Related Experiment Video
Updated: Mar 22, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Immune based therapy for melanoma.
Robert Ancuceanu1, Monica Neagu
1University of Medicine and Pharmacy "Carol Davila", Bucharest, Faculty of Pharmacy, Bucharest, Romania.
Recent advancements in advanced melanoma treatment offer new hope. Several immunotherapies, including ipilimumab and anti-PD1 inhibitors, have been approved, with more therapies in development.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Advanced melanoma previously had limited treatment options and a poor prognosis.
- Recent therapeutic progress has significantly improved outcomes and outlook for patients.
Purpose of the Study:
- To review recent advancements in the treatment of advanced melanoma.
- To highlight novel therapeutic agents and their mechanisms of action.
Main Methods:
- Review of recently authorized therapies for advanced melanoma.
- Discussion of immunotherapeutic agents such as ipilimumab and anti-PD1 inhibitors.
- Inclusion of oncolytic immunotherapy (talimogene laherparepvec) and combination strategies.
Main Results:
Conclusions:
- Current therapeutic options for advanced melanoma have expanded significantly.
- Immunotherapy and combination approaches represent the forefront of treatment innovation.
- Ongoing research into novel molecules and strategies promises further benefits for patients.

